GRAIL, Inc. (GRAL)
| Market Cap | 3.03B +64.0% |
| Revenue (ttm) | 156.12M +19.4% |
| Net Income | -395.33M |
| EPS | -10.31 |
| Shares Out | 42.92M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 25,037 |
| Open | 70.00 |
| Previous Close | 71.96 |
| Day's Range | 69.69 - 71.69 |
| 52-Week Range | 29.95 - 118.84 |
| Beta | 3.22 |
| Analysts | Buy |
| Price Target | 67.75 (-4.17%) |
| Earnings Date | Aug 11, 2026 |
About GRAL
GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients with clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development. In addition, its precision oncology... [Read more]
Financial Performance
In 2025, GRAIL's revenue was $147.17 million, an increase of 17.18% compared to the previous year's $125.60 million. Losses were -$408.35 million, -79.85% less than in 2024.
Financial StatementsAnalyst Summary
According to 9 analysts, the average rating for GRAL stock is "Buy." The 12-month stock price target is $67.75, which is a decrease of -4.17% from the latest price.
News
Grail’s Gallery cancer detection test adopted by Priority Health
Grail (GRAL) announced a collaboration with Priority Health, a nonprofit health plan and the third largest provider-sponsored health plan in the nation, to make Grail’s Galleri multi-cancer early dete...
Priority Health Collaborates With GRAIL as the First Michigan Health Plan to Offer the Galleri® Multi-Cancer Early Detection Blood Test to Employer Plans
MENLO PARK, Calif., July 16, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced a collaboration with Pr...
Grail price target raised to $88 from $69 at TD Cowen
TD Cowen analyst Dan Brennan raised the firm’s price target on Grail (GRAL) to $88 from $69 and keeps a Buy rating on the shares. The firm adjusted targets in…
Grail price target raised to $65 from $58 at Mizuho
Mizuho raised the firm’s price target on Grail (GRAL) to $65 from $58 and keeps a Neutral rating on the shares. The firm adjusted targets in the medical device and…
SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of August 4, 2026 in Grail, Inc. Lawsuit - GRAL
Wall Street's Reassessment of Grail: How Analyst Expectations Built on Positive NHS-Galleri Representations Collapsed Alongside GRAL's $51.32 Per-Share Decline Wall Street's Reassessment of Grail: How...
$GRAL Fraud Notification: GRAIL, Inc. Sued for Securities Fraud After Trial Results Spark a 50% Stock Drop – Investors Notified to Contact BFA Law by August 4
A securities fraud class action lawsuit has been filed on behalf of GRAIL investors after its stock plummeted 50% because GRAIL allegedly misled investors relating to GRAIL's NHS-Galleri cancer trial,...
GRAIL, Inc. (GRAL) Securities Fraud: Contact Berger Montague to Discuss Your Rights
Philadelphia, Pennsylvania--(Newsfile Corp. - July 2, 2026) - National plaintiffs' law firm Berger Montague PC announces a class action lawsuit against GRAIL, Inc. (NASDAQ: GRAL) ("GRAIL" or the "Comp...
GRAL Investors Have Rights – If You Lost Money Investing in Grail, Inc. Contact Robbins LLP for Information About Recovering Your Losses
SAN DIEGO, July 01, 2026 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Grail, Inc. (NASDAQ: GRAL) se...
GRAIL Completes $110 Million Equity Financing With Samsung Entities
MENLO PARK, Calif., June 25, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced the closing of its prev...
GRAIL Transcript: AGM 2026
The meeting covered director elections, auditor ratification, and governance procedures. Both proposals passed, with final results to be filed with the SEC. No shareholder questions were addressed during the session.
GRAL Breaking News: GRAIL, Inc. Sued for Securities Fraud after Trial Results Lead to 50% Stock Drop – Investors Notified to Contact BFA Law
NEW YORK--(BUSINESS WIRE)---- $GRAL #BFA--GRAIL, Inc. Sued for Securities Fraud after Trial Results Lead to 50% Stock Drop – Investors Notified to Contact BFA Law.
GRAIL, INC. (GRAL) INVESTOR ALERT Investors With Large Losses in GRAIL, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights
NEW YORK, June 10, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquir...
GRAIL Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
Significant reductions in late-stage cancer and emergency presentations were demonstrated in a large RCT, supporting clinical utility and future coverage. FDA approval and international expansion are key priorities, with strong self-pay and digital health growth driving near-term volumes.
Grail initiated with a Neutral at Goldman Sachs
Goldman Sachs initiated coverage of Grail (GRAL) with a Neutral rating and $60 price target While the company’s Galleri test has had success in penetrating the self-pay market for multi-cancer…
GRAIL Transcript: Jefferies Global Healthcare Conference 2026
Recent results show strong volume and revenue growth, with major clinical studies demonstrating significant early-stage cancer detection and reduced late-stage incidence. Regulatory progress continues, with FDA review underway and expanded reimbursement expected to drive broader adoption and margin improvement.
Grail assumed with a Peer Perform at Wolfe Research
Wolfe Research assumed coverage of Grail (GRAL) with a Peer Perform rating and no price target The company need payor support to scale, says Wolfe, which prefers to monitor Grail’s…
GRAIL Transcript: Study result
Results from NHS-Galleri and PATHFINDER 2 trials show Galleri MCED testing significantly increases early cancer detection, reduces stage 4 and emergency-presenting cancers, and maintains high specificity and PPV. Most detected cancers lack current screening options, supporting broad clinical utility.
GRAIL Press release: Study result
GRAIL issued a press release on May 31, 2026, disclosing material business information to investors.
GRAIL Slides: Study result
GRAIL has posted slides in relation to its latest quarterly earnings report, which was published on May 31, 2026.
Grail presents ‘positive’ performance, safety results from Pathfinder 2 study
GRAIL (GRAL) announced that “positive” performance and safety results from the analysis of the full 35,878 cohort of its registrational Pathfinder 2 study are being presented during an oral session…
Grail reports results from NHS-Galleri trial in presentation at ASCO meeting
GRAIL (GRAL) announced detailed clinical utility, performance and safety results from its NHS-Galleri trial in an oral presentation at the 2026 American Society of Clinical Oncology, ASCO, Annual Meet...
GRAIL Presents PATHFINDER 2 Results of More Than 35,000 Participants Showing the Galleri® Test Substantially Increased Cancer Detection With Robust Performance and Favorable Safety at 2026 ASCO Annual Meeting
The Galleri Multi-Cancer Early Detection (MCED) Test Increased Cancer Detection 6.5 Fold When Added to Recommended Screenings for Breast, Colorectal, Cervical and Lung Cancer 71% of the New Cancers De...
GRAIL Reports Full Results From NHS-Galleri Trial Demonstrating Substantial Reduction in Stage IV Cancer Diagnoses at 2026 ASCO Annual Meeting
No Reduction Observed in Combined Primary Endpoint of Stage III/IV Cancers in Aggregate; However, Decreases Observed Beyond the Prevalent Screening Round Annual Galleri ® Blood Test Reduced Stage IV...